|
1）Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet. 2009; 41: 591-5
|
|
|
|
2）Hu L, Zhai X, Liu J, et al. Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development. Hepatology. 2012; 55: 1426-31
|
|
|
|
|
|
3）Guo X, Zhang Y, Li J, et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. Hepatology. 2011; 53: 422-8
|
|
|
|
|
|
4）OBrien TR, Kohaar I, Pfeiffer RM, et al. Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver. Genes Immun. 2011(in press)
|
|
|
|
|
|
5）Nishida N, Sawai H, Matsuura K, et al. Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS ONE. 2012; 7: 1-8
|
|
|
|
|
|
6）Thomas R, Thio CL, Apps R, et al. A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection. J Virol. 2012; 86: 6979-85
|
|
|
|
|
|
7）Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41: 1105-9
|
|
|
|
|
|
8）Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461: 399-401
|
|
|
|
|
|
9）Stuppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41: 1100-4
|
|
|
|
|
|
10）Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, detemied by a suitable genotyping method, is a better predictor for response to pegylated interferon-a/ribavirin therapy in Japanese patients than other SNPs associated with IL28B. J Clin Microbiol. 2011; 49: 1853-60
|
|
|
|
|
|
11）Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and geneteic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010; 52; 421-9
|
|
|
|
|
|
12）Saito H, Ito K, Sugiyama M, et al. Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients. Hepatol Res. 2012; 42: 958-65
|
|
|
|
|
13）Sugiyama M,Tanaka Y, Wakita T, et al. Genetic variation of the IL-28B promoter affecting gene expression. PLoS One. 2011; 6: e26620
|
|
|
|
|
|
14）Asahina Y, Tsuchiya K, Muraoka M, et al. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology. 2012; 55: 20-9
|
|
|
|
|
|
15）Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastro-enterology. 2010; 139: 499-509
|
|
|
|
|
|
16）Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461: 798-801
|
|
|
|
|
|
17）Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010; 139: 1586-92
|
|
|
|
|
|
18）Siren J, Pirhonen J, Julkunen I, et al. IFN-α regulates TLR-dependent gene expression of IFN-α, IFN-β, IL-28, IL-29. J Immunol. 2005; 174: 1032-937
|
|
|
|
|
|
19）Thomas E, Gonzalez VD, Li Q, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology. 2012; 142: 978-88
|
|
|
|
|
|
20）Fukuhara T, Ikegami T, Morita K, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastro-enterology. 2010; 139: 1577-85
|
|
|
|
|
|
21）Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010; 464: 405-8
|
|
|
|
|
|
22）Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribaviirn-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients. Gastro-enterology. 2010; 139: 1190-7
|
|
|
|
|
|
23）Sakamoto N, Tanaka Y, Nakagawa M, et al. ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res. 2010; 40: 1063-70
|
|
|
|
|
|
24）Suzuki F, Suzuki Y, Akuta N, et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology. 2011; 53: 415-21
|
|
|
|
|
|
25）Kumar V, Kato N, Urabe Y, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 2011; 43: 455-8
|
|
|
|
|
|
26）Miki D, Ochi H, Hayes CN, et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet. 2011; 43: 797-800
|
|
|
|
|
|
27）Marcolongo M, Young B, Dal Pero F, et al. A seven-gene signature (cirrhosis risk group) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology. 2009; 50: 1038-44
|
|
|
|
|